These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 34741682)

  • 1. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
    Xu B
    Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 4. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
    Goparaju K; Caimi PF
    Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
    Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
    Ahmed N; Hamadani M
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1313-1320. PubMed ID: 34597242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
    Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loncastuximab Tesirine: First Approval.
    Lee A
    Drugs; 2021 Jul; 81(10):1229-1233. PubMed ID: 34143407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
    Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
    Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.
    Sermer D; Elavalakanar P; Abramson JS; Palomba ML; Salles G; Arnason J
    Blood Rev; 2023 Jan; 57():101002. PubMed ID: 35989138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W
    Expert Opin Biol Ther; 2021 Apr; 21(4):455-463. PubMed ID: 33554668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loncastuximab tesirine for diffuse large B-cell lymphoma.
    Zurko J; Hamadani M
    Drugs Today (Barc); 2021 Dec; 57(12):733-743. PubMed ID: 34909802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Baek GT; Huang IJ; Gopal AK
    Cancer; 2023 Aug; 129(15):2279-2283. PubMed ID: 37208793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
    Lu Q; Huang H; Tang S; Wang Y; Yang DH
    Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
    Pirosa MC; Stathis A; Zucca E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
    Watkins MP; Bartlett NL
    Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
    Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.